Alnylam Pharmaceuticals (ALNY) Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Rnai-Mediating Double-Stranded Molecules Comprising Up To 25 Base Pairs
8/20/2014 8:36:55 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Tuschl et al. patent application 13/725,262. The ’262 patent application includes newly allowed claims directed to compositions that mediate RNAi, and comprising a double-stranded molecule with up to 25 base pairs and at least one nucleotide analogue. Specifically, the newly allowed patent application broadly covers small interfering RNA (“siRNA”) molecules of various designs, including so-called “dicer substrate” RNAi triggers (Amarzguioui et al., Nat Protoc. 2006;1(2):508-17; Rose et al., Nucleic Acids Res. 2005 Jul 26;33(13):4140-56) and double-stranded, RNAi-mediating molecules containing moieties that include “unlocked nucleobase analogs” (“UNA”) amongst other naturally or non-naturally occurring nucleotide analogues.
Hey, check out all the engineering jobs. Post your resume today!
comments powered by